204 related articles for article (PubMed ID: 22146831)
1. Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study).
Schleiermacher G; Michon J; Ribeiro A; Pierron G; Mosseri V; Rubie H; Munzer C; Bénard J; Auger N; Combaret V; Janoueix-Lerosey I; Pearson A; Tweddle DA; Bown N; Gerrard M; Wheeler K; Noguera R; Villamon E; Cañete A; Castel V; Marques B; de Lacerda A; Tonini GP; Mazzocco K; Defferrari R; de Bernardi B; di Cataldo A; van Roy N; Brichard B; Ladenstein R; Ambros I; Ambros P; Beiske K; Delattre O; Couturier J
Br J Cancer; 2011 Dec; 105(12):1940-8. PubMed ID: 22146831
[TBL] [Abstract][Full Text] [Related]
2. Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification.
Defferrari R; Mazzocco K; Ambros IM; Ambros PF; Bedwell C; Beiske K; Bénard J; Berbegall AP; Bown N; Combaret V; Couturier J; Erminio G; Gambini C; Garaventa A; Gross N; Haupt R; Kohler J; Jeison M; Lunec J; Marques B; Martinsson T; Noguera R; Parodi S; Schleiermacher G; Tweddle DA; Valent A; Van Roy N; Vicha A; Villamon E; Tonini GP
Br J Cancer; 2015 Jan; 112(2):290-5. PubMed ID: 25356804
[TBL] [Abstract][Full Text] [Related]
3. Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification.
Schleiermacher G; Michon J; Huon I; d'Enghien CD; Klijanienko J; Brisse H; Ribeiro A; Mosseri V; Rubie H; Munzer C; Thomas C; Valteau-Couanet D; Auvrignon A; Plantaz D; Delattre O; Couturier J;
Br J Cancer; 2007 Jul; 97(2):238-46. PubMed ID: 17579628
[TBL] [Abstract][Full Text] [Related]
4. Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1.
Rubie H; De Bernardi B; Gerrard M; Canete A; Ladenstein R; Couturier J; Ambros P; Munzer C; Pearson AD; Garaventa A; Brock P; Castel V; Valteau-Couanet D; Holmes K; Di Cataldo A; Brichard B; Mosseri V; Marquez C; Plantaz D; Boni L; Michon J
J Clin Oncol; 2011 Feb; 29(4):449-55. PubMed ID: 21172879
[TBL] [Abstract][Full Text] [Related]
5. cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma.
Chen QR; Bilke S; Wei JS; Whiteford CC; Cenacchi N; Krasnoselsky AL; Greer BT; Son CG; Westermann F; Berthold F; Schwab M; Catchpoole D; Khan J
BMC Genomics; 2004 Sep; 5():70. PubMed ID: 15380028
[TBL] [Abstract][Full Text] [Related]
6. The impact of surgical radicality on outcome in childhood neuroblastoma.
von Schweinitz D; Hero B; Berthold F
Eur J Pediatr Surg; 2002 Dec; 12(6):402-9. PubMed ID: 12548494
[TBL] [Abstract][Full Text] [Related]
7. Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable
Ambros IM; Tonini GP; Pötschger U; Gross N; Mosseri V; Beiske K; Berbegall AP; Bénard J; Bown N; Caron H; Combaret V; Couturier J; Defferrari R; Delattre O; Jeison M; Kogner P; Lunec J; Marques B; Martinsson T; Mazzocco K; Noguera R; Schleiermacher G; Valent A; Van Roy N; Villamon E; Janousek D; Pribill I; Glogova E; Attiyeh EF; Hogarty MD; Monclair TF; Holmes K; Valteau-Couanet D; Castel V; Tweddle DA; Park JR; Cohn S; Ladenstein R; Beck-Popovic M; De Bernardi B; Michon J; Pearson ADJ; Ambros PF
J Clin Oncol; 2020 Nov; 38(31):3685-3697. PubMed ID: 32903140
[TBL] [Abstract][Full Text] [Related]
8. Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project.
Schleiermacher G; Mosseri V; London WB; Maris JM; Brodeur GM; Attiyeh E; Haber M; Khan J; Nakagawara A; Speleman F; Noguera R; Tonini GP; Fischer M; Ambros I; Monclair T; Matthay KK; Ambros P; Cohn SL; Pearson AD
Br J Cancer; 2012 Oct; 107(8):1418-22. PubMed ID: 22976801
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study.
Berbegall AP; Bogen D; Pötschger U; Beiske K; Bown N; Combaret V; Defferrari R; Jeison M; Mazzocco K; Varesio L; Vicha A; Ash S; Castel V; Coze C; Ladenstein R; Owens C; Papadakis V; Ruud E; Amann G; Sementa AR; Navarro S; Ambros PF; Noguera R; Ambros IM
Br J Cancer; 2018 May; 118(11):1502-1512. PubMed ID: 29755120
[TBL] [Abstract][Full Text] [Related]
10. Treatment of children over the age of one year with unresectable localised neuroblastoma without MYCN amplification: results of the SIOPEN study.
Kohler JA; Rubie H; Castel V; Beiske K; Holmes K; Gambini C; Casale F; Munzer C; Erminio G; Parodi S; Navarro S; Marquez C; Peuchmaur M; Cullinane C; Brock P; Valteau-Couanet D; Garaventa A; Haupt R
Eur J Cancer; 2013 Nov; 49(17):3671-9. PubMed ID: 23907002
[TBL] [Abstract][Full Text] [Related]
11. The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma.
Bogen D; Brunner C; Walder D; Ziegler A; Abbasi R; Ladenstein RL; Noguera R; Martinsson T; Amann G; Schilling FH; Ussowicz M; Benesch M; Ambros PF; Ambros IM
Int J Cancer; 2016 Jul; 139(1):153-63. PubMed ID: 26910568
[TBL] [Abstract][Full Text] [Related]
12. A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines.
Sugimoto T; Gotoh T; Yagyu S; Kuroda H; Iehara T; Hosoi H; Ohta S; Ohira M; Nakagawara A
Cancer Lett; 2013 Apr; 331(1):115-21. PubMed ID: 23268333
[TBL] [Abstract][Full Text] [Related]
13. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
[TBL] [Abstract][Full Text] [Related]
14. Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project.
Thompson D; Vo KT; London WB; Fischer M; Ambros PF; Nakagawara A; Brodeur GM; Matthay KK; DuBois SG
Cancer; 2016 Mar; 122(6):935-45. PubMed ID: 26709890
[TBL] [Abstract][Full Text] [Related]
15. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
Spitz R; Hero B; Ernestus K; Berthold F
Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
[TBL] [Abstract][Full Text] [Related]
16. 2p24 Gain region harboring MYCN gene compared with MYCN amplified and nonamplified neuroblastoma: biological and clinical characteristics.
Jeison M; Ash S; Halevy-Berko G; Mardoukh J; Luria D; Avigad S; Feinberg-Gorenshtein G; Goshen Y; Hertzel G; Kapelushnik J; Ben Barak A; Attias D; Steinberg R; Stein J; Stark B; Yaniv I
Am J Pathol; 2010 Jun; 176(6):2616-25. PubMed ID: 20395439
[TBL] [Abstract][Full Text] [Related]
17. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
[TBL] [Abstract][Full Text] [Related]
18. Coamplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma.
Weber A; Imisch P; Bergmann E; Christiansen H
J Clin Oncol; 2004 Jul; 22(13):2681-90. PubMed ID: 15226335
[TBL] [Abstract][Full Text] [Related]
19. Whole chromosome alterations predict survival in high-risk neuroblastoma without MYCN amplification.
Bilke S; Chen QR; Wei JS; Khan J
Clin Cancer Res; 2008 Sep; 14(17):5540-7. PubMed ID: 18765546
[TBL] [Abstract][Full Text] [Related]
20. Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project.
Vo KT; Matthay KK; Neuhaus J; London WB; Hero B; Ambros PF; Nakagawara A; Miniati D; Wheeler K; Pearson AD; Cohn SL; DuBois SG
J Clin Oncol; 2014 Oct; 32(28):3169-76. PubMed ID: 25154816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]